Abstract
Development of potent, selective and orally bioactive dipeptidyl Peptidase IV inhibitors as antihyperglycemic agents is challenging task due to potential side effects are associated with them. It may result from other prolyldipeptidases of DPP-4 include DPP-2, DPP-8 and DPP-9. To resolve the selectivity issue in different DPP enzymes hologram quantitative structure-activity relationship studies were carried out on a series of potent and selective DPP-4 ligands. To measure selectivity between two kinds of enzyme selectivity data of DPP-4 over DPP-2, DPP-8 and DPP-9 were calculated and best HQSAR models were generated with significant correlation coefficients. The statistical results of the three models showed the best prediction and fitness for the selectivity activities. Docking studies were carried out on conformationally rigid 3-azabicyclo [3.1.0] hexane derivatives which suggested the substitution pattern on P1 and P2 fragment. The finally QSAR model, along with the information obtained from contribution maps and docking studies should be useful for the design of novel DPP-4 ligands having improved selectivity without side effects.
Keywords: HQSAR, 3-azabicyclo [3.1.0] hexane derivatives, Fragment based design, Selectivity, DPP-4 inhibitors, Docking.
Letters in Drug Design & Discovery
Title:Fragment Based HQSAR Modeling and Docking Analysis of Conformationally Rigid 3-azabicyclo [3.1.0] Hexane Derivatives to Design Selective DPP-4 Inhibitors
Volume: 11 Issue: 2
Author(s): Manjunath Ghate and Shailesh V. Jain
Affiliation:
Keywords: HQSAR, 3-azabicyclo [3.1.0] hexane derivatives, Fragment based design, Selectivity, DPP-4 inhibitors, Docking.
Abstract: Development of potent, selective and orally bioactive dipeptidyl Peptidase IV inhibitors as antihyperglycemic agents is challenging task due to potential side effects are associated with them. It may result from other prolyldipeptidases of DPP-4 include DPP-2, DPP-8 and DPP-9. To resolve the selectivity issue in different DPP enzymes hologram quantitative structure-activity relationship studies were carried out on a series of potent and selective DPP-4 ligands. To measure selectivity between two kinds of enzyme selectivity data of DPP-4 over DPP-2, DPP-8 and DPP-9 were calculated and best HQSAR models were generated with significant correlation coefficients. The statistical results of the three models showed the best prediction and fitness for the selectivity activities. Docking studies were carried out on conformationally rigid 3-azabicyclo [3.1.0] hexane derivatives which suggested the substitution pattern on P1 and P2 fragment. The finally QSAR model, along with the information obtained from contribution maps and docking studies should be useful for the design of novel DPP-4 ligands having improved selectivity without side effects.
Export Options
About this article
Cite this article as:
Ghate Manjunath and V. Jain Shailesh, Fragment Based HQSAR Modeling and Docking Analysis of Conformationally Rigid 3-azabicyclo [3.1.0] Hexane Derivatives to Design Selective DPP-4 Inhibitors, Letters in Drug Design & Discovery 2014; 11 (2) . https://dx.doi.org/10.2174/15701808113109990051
DOI https://dx.doi.org/10.2174/15701808113109990051 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Meet Our Editorial Board Member
Infectious Disorders - Drug Targets Patent Selections
Recent Patents on CNS Drug Discovery (Discontinued) Antimicrobial Plant Metabolites: Structural Diversity and Mechanism of Action
Current Medicinal Chemistry A Case of Fingolimod-associated Cryptococcal Meningitis
Current HIV Research The Use of Chronobiotics in the Resynchronization of the Sleep/Wake Cycle. Therapeutical Application in the Early Phases of Alzheimer's Disease
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery The GABAergic System and the Gastrointestinal Physiopathology
Current Pharmaceutical Design Achilles Tendon in Diabetes
Current Diabetes Reviews Basolateral Aggregated Rat Amyloidβ(1-42) Potentiates Transmigration of Primary Rat Monocytes through a Rat Blood-Brain Barrier
Current Neurovascular Research Management of Obesity
Current Respiratory Medicine Reviews Editorial [Hot Topic: Endocrine Disruption and Reproduction (Guest Editor: Peter C.K. Leung)]
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Transcription Factors as Targets for Cancer Therapy: AP-1 a Potential Therapeutic Target
Current Cancer Therapy Reviews Application of Bacterial Nanocellulose in Cancer Drug Delivery: A Review
Current Pharmaceutical Design The Effects of Herbal Medicines on Women Sexual Dysfunction: A Systematic Review
Current Drug Discovery Technologies Editorial [Hot Topic: Novel Peptides and Proteins in Diabetes Mellitus (Guest Editors: Po Sing Leung and Marc de Gasparo)]
Current Protein & Peptide Science New Antihypertensive Drugs Under Development
Current Medicinal Chemistry Human Leptin Regulation and Promise in Pharmacotherapy
Current Drug Targets Recombinant Hepatitis B Vaccination in Renal Failure Patients
Current Pharmaceutical Biotechnology Curcumin Suppresses Epithelial Growth Factor Receptor (EGFR) and Proliferative Protein (Ki 67) in Acute Lung Injury and Lung Fibrosis <i>In vitro</i> and <i>In vivo</i>
Endocrine, Metabolic & Immune Disorders - Drug Targets Influence of Vanin-1 and Catalytic Products in Liver During Normal and Oxidative Stress Conditions
Current Medicinal Chemistry Biomarkers of Protein Oxidation in Human Disease
Current Molecular Medicine